1. FAP holds significant promise in the diagnosis and treatment of cancer patients, emerging as the most promising target following PSMA and SSTR.
Precision-guided “nuclear weapons” for targeted destruction of cancer cells
2. Nectin-4 is highly expressed in multiple solid tumors and exhibits high tumor specificity.
Advantages of Nuclear Medicine Therapy:
The company has two radiopharmaceutical pipelines that have entered the Investigational New Drug (IND) stage, completing studies involving 90 patients. These studies demonstrated excellent tumor targeting and rapid metabolism characteristics. The first radiopharmaceutical is slated for regulatory submission in 2028, with multiple additional radiopharmaceutical projects poised to enter the clinical stage.
Principle of Radiopharmaceutical Therapy: By conjugating a radionuclide to a targeting ligand via a linker and chelator, radiopharmaceuticals accumulate at the therapeutic site within the body, enabling precise targeting and effective elimination of target cells. It represents the only class of drugs in clinical practice capable of integrated diagnosis and treatment.
Radionuclide Drug Conjugates (RDC)：consist of four components: a radioisotope, a chelator, a linker, and a biological targeting moiety.
